Abstract：
UNASSIGNED: Isolated infected iliac artery aneurysms (IIIAAs) are extremely rare, life-threatening, and intractable. This study aimed to evaluate the outcomes of endovascular treatment in patients with IIIAAs.
UNASSIGNED: A retrospective study was conducted for all patients who underwent endovascular treatment for IIIAAs between June 2012 and June 2022 in 3 hospitals. The clinical data and follow-up outcomes were reviewed and assessed.
UNASSIGNED: Fifteen patients were included in this study. The median age was 69 years, 12 patients (80%) were men, and 8 (53%) had hypertension. Most of the patients presented with abdominal or lumbar pain (87%) and fever (60%). The offending pathogen was identified in 11 patients (73%). Fifteen patients had a total of 16 IIIAAs, with 12 (75%) involving the common iliac artery. The immediate technical success rate was 100%, and the 30-day mortality was 7%. Infection-related complications occurred in 2 patients (13%) during hospitalization who were treated by open surgery at a later stage. The median follow-up was 23 months (range: 6-80 months, mean: 32 ± 25 months). Aneurysm recurrence was identified in one patient (7%) 5 months after endovascular repair. It was managed by endovascular stent-graft repair with percutaneous catheter drainage. No patients died during the follow-up period.
UNASSIGNED: Endovascular treatment is feasible, safe, and effective for patients with IIIAAs, achieving acceptable clinical outcomes. Infection surveillance with essential reintervention should be considered for potential infection-related complications.
CONCLUSIONS: This study first reported that 15 patients underwent endovascular treatment for primary isolated infected iliac artery aneurysms (IIIAAs). It showed a good early and midterm outcomes. This is the first and largest multi-center study and the first literature review of IIIAAs. It provides an evidence that endovascular treatment is feasible, safe, and effective to treat IIIAAs. It suggests endovascular treatment is a promising alternative or a bridge to conventional open surgery for IIIAAs. This may promote endovascular therapy in the management of IIIAAs. It would help clinicians to make an appropriate treatment choice for IIIAAs.
UNASSIGNED: A retrospective study was conducted for all patients who underwent endovascular treatment for IIIAAs between June 2012 and June 2022 in 3 hospitals. The clinical data and follow-up outcomes were reviewed and assessed.
UNASSIGNED: Fifteen patients were included in this study. The median age was 69 years, 12 patients (80%) were men, and 8 (53%) had hypertension. Most of the patients presented with abdominal or lumbar pain (87%) and fever (60%). The offending pathogen was identified in 11 patients (73%). Fifteen patients had a total of 16 IIIAAs, with 12 (75%) involving the common iliac artery. The immediate technical success rate was 100%, and the 30-day mortality was 7%. Infection-related complications occurred in 2 patients (13%) during hospitalization who were treated by open surgery at a later stage. The median follow-up was 23 months (range: 6-80 months, mean: 32 ± 25 months). Aneurysm recurrence was identified in one patient (7%) 5 months after endovascular repair. It was managed by endovascular stent-graft repair with percutaneous catheter drainage. No patients died during the follow-up period.
UNASSIGNED: Endovascular treatment is feasible, safe, and effective for patients with IIIAAs, achieving acceptable clinical outcomes. Infection surveillance with essential reintervention should be considered for potential infection-related complications.
CONCLUSIONS: This study first reported that 15 patients underwent endovascular treatment for primary isolated infected iliac artery aneurysms (IIIAAs). It showed a good early and midterm outcomes. This is the first and largest multi-center study and the first literature review of IIIAAs. It provides an evidence that endovascular treatment is feasible, safe, and effective to treat IIIAAs. It suggests endovascular treatment is a promising alternative or a bridge to conventional open surgery for IIIAAs. This may promote endovascular therapy in the management of IIIAAs. It would help clinicians to make an appropriate treatment choice for IIIAAs.
摘要：
■孤立的感染性髂动脉瘤（IIIAAs）极为罕见，危及生命,而且很棘手.本研究旨在评估IIIAAs患者的血管内治疗结果。
■对2012年6月至2022年6月在3家医院接受IIIA血管内治疗的所有患者进行了回顾性研究。对临床资料和随访结果进行回顾和评估。
■本研究包括15例患者。中位年龄为69岁,12名患者（80％）为男性，和8（53％）有高血压。大多数患者表现为腹部或腰部疼痛（87％）和发烧（60％）。在11名患者（73％）中发现了令人讨厌的病原体。15名患者共有16个IIIAAs，12例（75%）累及髂总动脉。即时技术成功率为100%,30天死亡率为7%。2例（13％）住院期间发生感染相关并发症，后期接受开放手术治疗。中位随访时间为23个月（范围：6-80个月，平均：32±25个月）。在血管内修复后5个月，一名患者（7％）发现动脉瘤复发。通过经皮导管引流的血管内支架修复来管理。随访期间无患者死亡。
■血管内治疗是可行的，安全,对IIIAAs患者有效，达到可接受的临床结果。对于潜在的感染相关并发症，应考虑进行感染监测并进行必要的再干预。
结论：本研究首次报道15例患者接受了原发性孤立性髂动脉瘤（IIIAAs）的血管内治疗。它显示了良好的早期和中期结果。这是第一个也是最大的多中心研究，也是IIIAAs的第一个文献综述。它提供了血管内治疗是可行的证据，安全,并有效治疗IIIAAs。这表明血管内治疗是IIIAAs常规开放手术的有希望的替代方案或桥梁。这可以促进IIIAAs管理中的血管内治疗。这将有助于临床医生为IIIAAs做出适当的治疗选择。
■对2012年6月至2022年6月在3家医院接受IIIA血管内治疗的所有患者进行了回顾性研究。对临床资料和随访结果进行回顾和评估。
■本研究包括15例患者。中位年龄为69岁,12名患者（80％）为男性，和8（53％）有高血压。大多数患者表现为腹部或腰部疼痛（87％）和发烧（60％）。在11名患者（73％）中发现了令人讨厌的病原体。15名患者共有16个IIIAAs，12例（75%）累及髂总动脉。即时技术成功率为100%,30天死亡率为7%。2例（13％）住院期间发生感染相关并发症，后期接受开放手术治疗。中位随访时间为23个月（范围：6-80个月，平均：32±25个月）。在血管内修复后5个月，一名患者（7％）发现动脉瘤复发。通过经皮导管引流的血管内支架修复来管理。随访期间无患者死亡。
■血管内治疗是可行的，安全,对IIIAAs患者有效，达到可接受的临床结果。对于潜在的感染相关并发症，应考虑进行感染监测并进行必要的再干预。
结论：本研究首次报道15例患者接受了原发性孤立性髂动脉瘤（IIIAAs）的血管内治疗。它显示了良好的早期和中期结果。这是第一个也是最大的多中心研究，也是IIIAAs的第一个文献综述。它提供了血管内治疗是可行的证据，安全,并有效治疗IIIAAs。这表明血管内治疗是IIIAAs常规开放手术的有希望的替代方案或桥梁。这可以促进IIIAAs管理中的血管内治疗。这将有助于临床医生为IIIAAs做出适当的治疗选择。
